Novartis Reports Positive Phase III Results for Remibrutinib in Relapsing Multiple Sclerosis

Novartis announced positive topline results from its Phase III REMODEL-1 and REMODEL-2 trials for remibrutinib, an oral Bruton's tyrosine kinase (BTK) inhibitor, in adults with relapsing multiple sclerosis (RMS). The trials met their primary endpoint, significantly reducing the annualized relapse rate and inflammatory brain lesions compared to teriflunomide, with a favorable safety profile.